Anti-cytokine autoantibodies in a patient with a heterozygous NFKB2 mutation

We report a family with a heterozygous NFKB2 mutation in which anti-cytokine autoantibodies were identified in one individual. Rituximab therapy for autoantibodies led to a reduction in anti-cytokine autoantibodies and a marked improvement in infectious susceptibility.

http://ift.tt/2AXO2RX